trimipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
substances of the imipramine group 2758 739-71-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trimipramine
  • rhotrimine
  • trimeprimine
  • trimeproprimine
  • trimipramine maleate
  • surmontil
  • trimipramine maleate salt
  • trimipramine mesylate
  • trimipramine monohydrochloride
Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.
  • Molecular weight: 294.44
  • Formula: C20H26N2
  • CLOGP: 5.44
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.05
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O
0.15 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 11.31 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 23 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK12,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK 41
kinase-selectivity-class PDK4 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1

Approvals:

DateAgencyCompanyOrphan
June 12, 1979 FDA ODYSSEY PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Deafness transitory 127.67 17.60 28 4786 2015 90621618
Functional gastrointestinal disorder 102.43 17.60 28 4786 5034 90618599
Abnormal loss of weight 94.16 17.60 28 4786 6795 90616838
Coma 89.98 17.60 53 4761 72579 90551054
Gastrointestinal pain 80.50 17.60 28 4786 11178 90612455
Traumatic coma 76.62 17.60 11 4803 61 90623572
Feeding disorder 68.33 17.60 28 4786 17484 90606149
Musculoskeletal disorder 59.29 17.60 27 4787 21742 90601891
Pharyngitis 59.08 17.60 27 4787 21920 90601713
Eating disorder 52.76 17.60 27 4787 28046 90595587
Suicide attempt 51.63 17.60 38 4776 75361 90548272
Pneumonia aspiration 50.99 17.60 30 4784 40910 90582723
Somnolence 49.21 17.60 58 4756 209026 90414607
Hypophagia 49.18 17.60 28 4786 35909 90587724
Toxicity to various agents 49.06 17.60 68 4746 287778 90335855
Atrial septal defect 45.69 17.60 17 4797 8217 90615416
Drug interaction 45.15 17.60 64 4750 276389 90347244
Parachute mitral valve 43.02 17.60 7 4807 97 90623536
Electrocardiogram QT prolonged 39.71 17.60 32 4782 72424 90551209
Drug abuse 36.14 17.60 32 4782 82315 90541318
Coarctation of the aorta 35.93 17.60 8 4806 616 90623017
Congenital tricuspid valve incompetence 33.84 17.60 6 4808 142 90623491
Ear infection 32.39 17.60 28 4786 69747 90553886
Deafness 32.03 17.60 18 4796 22496 90601137
Polyglandular autoimmune syndrome type II 31.97 17.60 5 4809 53 90623580
Patent ductus arteriosus 31.21 17.60 11 4803 4558 90619075
Victim of sexual abuse 29.76 17.60 7 4807 688 90622945
Product prescribing error 27.18 17.60 18 4796 30127 90593506
Miosis 26.56 17.60 12 4802 9472 90614161
Ventricular septal defect 25.80 17.60 10 4804 5397 90618236
Paranasal sinus inflammation 25.09 17.60 6 4808 633 90623000
Gastrooesophageal reflux disease 24.91 17.60 37 4777 166300 90457333
Apathy 24.82 17.60 12 4802 11028 90612605
Sinobronchitis 24.53 17.60 6 4808 695 90622938
Incorrect dosage administered 23.87 17.60 8 4806 2852 90620781
Underdose 23.70 17.60 21 4793 53996 90569637
Intentional overdose 23.65 17.60 27 4787 93807 90529826
Prescription drug used without a prescription 22.86 17.60 8 4806 3247 90620386
Disturbance in attention 22.05 17.60 19 4795 47090 90576543
Hypertensive crisis 22.04 17.60 13 4801 17771 90605862
Adverse drug reaction 22.00 17.60 29 4785 116672 90506961
Shoulder arthroplasty 20.93 17.60 8 4806 4158 90619475
Product monitoring error 20.26 17.60 8 4806 4536 90619097
Depressed level of consciousness 20.15 17.60 22 4792 72762 90550871
Foramen magnum stenosis 19.96 17.60 4 4810 185 90623448
Cancer fatigue 19.80 17.60 4 4810 193 90623440
Dizziness 19.45 17.60 72 4742 589212 90034421
Junctional ectopic tachycardia 19.34 17.60 4 4810 217 90623416
Leukopenia 18.94 17.60 25 4789 100685 90522948
Haematoma 18.78 17.60 16 4798 39032 90584601
Tachycardia 18.00 17.60 31 4783 157642 90465991
Loss of consciousness 17.91 17.60 29 4785 140209 90483424
Foot operation 17.90 17.60 9 4805 8992 90614641
Post laminectomy syndrome 17.61 17.60 4 4810 337 90623296

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prescription drug used without a prescription 103.59 34.61 23 1456 2707 42617149
Drug interaction 71.96 34.61 65 1414 266934 42352922
Brain oedema 70.45 34.61 25 1454 16302 42603554
Toxicity to various agents 70.14 34.61 60 1419 229076 42390780
Restlessness 59.55 34.61 26 1453 29223 42590633
Testicular seminoma (pure) 48.08 34.61 8 1471 201 42619655
Pulmonary oedema 47.46 34.61 27 1452 53245 42566611
Suicide attempt 42.77 34.61 24 1455 46076 42573780
Screaming 35.12 34.61 9 1470 1938 42617918

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prescription drug used without a prescription 113.85 18.99 30 5019 5466 110578784
Toxicity to various agents 110.26 18.99 122 4927 480433 110103817
Drug interaction 109.66 18.99 124 4925 500059 110084191
Coma 105.19 18.99 66 4983 117803 110466447
Traumatic coma 68.68 18.99 10 5039 74 110584176
Suicide attempt 65.92 18.99 47 5002 103347 110480903
Deafness transitory 64.98 18.99 14 5035 1079 110583171
Brain oedema 63.02 18.99 30 5019 31068 110553182
Somnolence 55.42 18.99 68 4981 297381 110286869
Drug abuse 54.86 18.99 53 4996 177358 110406892
Testicular seminoma (pure) 47.43 18.99 8 5041 164 110584086
Pneumonia aspiration 47.37 18.99 35 5014 81198 110503052
Intentional overdose 43.63 18.99 41 5008 132460 110451790
Functional gastrointestinal disorder 41.26 18.99 14 5035 6035 110578215
Restlessness 36.81 18.99 26 5023 56233 110528017
Victim of sexual abuse 32.58 18.99 7 5042 532 110583718
Miosis 32.13 18.99 17 5032 21966 110562284
Gastrointestinal pain 32.10 18.99 14 5035 11846 110572404
Apathy 30.87 18.99 15 5034 16224 110568026
Abnormal loss of weight 30.69 18.99 13 5036 10244 110574006
Gastrooesophageal reflux disease 30.05 18.99 39 5010 179937 110404313
Shoulder arthroplasty 27.18 18.99 9 5040 3598 110580652
Electrocardiogram QT prolonged 27.16 18.99 29 5020 108931 110475319
Depressed level of consciousness 26.44 18.99 29 5020 112249 110472001
Deafness 26.43 18.99 16 5033 26693 110557557
Underdose 25.51 18.99 22 5027 63532 110520718
Completed suicide 25.18 18.99 42 5007 242339 110341911
Screaming 24.52 18.99 9 5040 4872 110579378
Foot operation 24.34 18.99 10 5039 7303 110576947
Feeding disorder 24.29 18.99 14 5035 21348 110562902
Eyelid bleeding 23.90 18.99 4 5045 78 110584172
Abdominal pain lower 23.85 18.99 17 5032 37266 110546984
Pulmonary oedema 23.70 18.99 26 5023 100633 110483617
Aggression 22.76 18.99 20 5029 59190 110525060
Incorrect dosage administered 22.59 18.99 8 5041 3910 110580340
Hypertensive crisis 22.58 18.99 14 5035 24358 110559892
Loss of consciousness 21.71 18.99 35 5014 196271 110387979
Product prescribing error 21.07 18.99 18 5031 51313 110532937
Musculoskeletal disorder 20.95 18.99 13 5036 22651 110561599
General physical health deterioration 20.77 18.99 54 4995 425241 110159009
Pharyngitis 19.73 18.99 13 5036 25085 110559165
Polyglandular autoimmune syndrome type II 19.00 18.99 3 5046 40 110584210

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA06 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
FDA EPC N0000175752 Tricyclic Antidepressant
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:78298 environmental contaminant

Related Drugs by ATC class:

N06AA Non-selective monoamine reuptake inhibitors 20 drugs
amineptineamitriptylineamoxapinebutriptylineclomipraminedesipraminedibenzepindimetacrinedosulepindoxepinimipramineimipramine oxide show all 20 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Depressive disorder indication 35489007
Neuralgia off-label use 16269008
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Bipolar disorder contraindication 13746004 DOID:3312
Electroconvulsive therapy contraindication 23835007
Hyperthyroidism contraindication 34486009 DOID:7998
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Schizophrenia contraindication 58214004 DOID:5419
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:557
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Hypomania contraindication 231496004
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 5.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 6.83 PDSP IUPHAR
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 5.61 IUPHAR CHEMBL
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 5.42 PDSP IUPHAR
Histamine H1 receptor GPCR ANTAGONIST Ki 8.85 PDSP
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel IC50 4.96 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.56 CHEMBL

External reference:

IDSource
4019962 VUID
N0000148047 NUI
D00394 KEGG_DRUG
521-78-8 SECONDARY_CAS_RN
4018060 VANDF
4019962 VANDF
C0041056 UMLSCUI
CHEBI:9738 CHEBI
CHEMBL644 ChEMBL_ID
DB00726 DRUGBANK_ID
CHEMBL1200948 ChEMBL_ID
D014299 MESH_DESCRIPTOR_UI
5584 PUBCHEM_CID
7317 IUPHAR_LIGAND_ID
1414 INN_ID
6S082C9NDT UNII
10834 RXNORM
2164 MMSL
5636 MMSL
72541 MMSL
d00873 MMSL
001507 NDDF
004605 NDDF
005363 NDDF
373550009 SNOMEDCT_US
734496007 SNOMEDCT_US
87831009 SNOMEDCT_US
90426002 SNOMEDCT_US
25332-13-2 SECONDARY_CAS_RN
6S082C9NDT INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trimipramine HUMAN PRESCRIPTION DRUG LABEL 1 51991-944 CAPSULE 25 mg ORAL ANDA 22 sections
Trimipramine HUMAN PRESCRIPTION DRUG LABEL 1 51991-945 CAPSULE 50 mg ORAL ANDA 22 sections
Trimipramine HUMAN PRESCRIPTION DRUG LABEL 1 51991-946 CAPSULE 100 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 64850-850 CAPSULE 25 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 64850-851 CAPSULE 50 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 64850-852 CAPSULE 100 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2061 CAPSULE 25 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2062 CAPSULE 50 mg ORAL ANDA 22 sections
Trimipramine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2063 CAPSULE 100 mg ORAL ANDA 22 sections